Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Clay Thorp. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Clay Thorp har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:CLSD / Clearside Biomedical, Inc. | Director | 176 141 |
US:PHAS / PhaseBio Pharmaceuticals Inc | Director | 36 693 |
US:VIGL / Vigil Neuroscience, Inc. | Director | 1 556 030 |
US:GTHX / G1 Therapeutics, Inc. | 10% Owner | 3 237 711 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Clay Thorp. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp CLSD / Clearside Biomedical, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i CLSD / Clearside Biomedical, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i CLSD / Clearside Biomedical, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Clay Thorp som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-02-24 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 15 000 | 176 141 | 9,31 | 0,92 | 13 800 | 162 050 | |
2023-09-25 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 10 000 | 40 522 | 32,76 | 0,86 | 8 600 | 34 849 | |
2023-05-19 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
M - Exercise | 3 750 | 36 693 | 11,38 | ||||
2022-12-21 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 14 000 | 30 522 | 84,74 | 1,02 | 14 266 | 31 102 | |
2022-12-19 |
|
4/A | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −32 873 | 4 951 547 | −0,66 | 4,43 | −145 627 | 21 935 353 |
2022-12-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
J - Other | 8 522 | 16 522 | 106,52 | ||||
2022-12-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
J - Other | −1 406 507 | 3 545 040 | −28,41 | ||||
2022-05-20 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Restricted Stock Units |
A - Award | 3 750 | 3 750 | |||||
2022-05-20 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy) |
A - Award | 17 500 | 17 500 | |||||
2022-05-17 |
|
4 | VIGL |
Vigil Neuroscience, Inc.
Common Stock |
P - Purchase | 14 893 | 1 556 030 | 0,97 | 2,97 | 44 189 | 4 616 897 | |
2022-05-17 |
|
4 | VIGL |
Vigil Neuroscience, Inc.
Common Stock |
P - Purchase | 21 802 | 1 541 137 | 1,43 | 2,76 | 60 221 | 4 256 929 | |
2022-03-28 |
|
4 | VIGL |
Vigil Neuroscience, Inc.
Common Stock |
P - Purchase | 3 000 | 3 000 | 7,20 | 21 604 | 21 604 | ||
2022-01-11 |
|
4 | VIGL |
Vigil Neuroscience, Inc.
Series B Preferred Stock |
C - Conversion | −926 506 | 0 | −100,00 | ||||
2022-01-11 |
|
4 | VIGL |
Vigil Neuroscience, Inc.
Series A Preferred Stock |
C - Conversion | −2 552 021 | 0 | −100,00 | ||||
2022-01-11 |
|
4 | VIGL |
Vigil Neuroscience, Inc.
Common Stock |
P - Purchase | 265 000 | 1 519 335 | 21,13 | 14,00 | 3 710 000 | 21 270 690 | |
2022-01-11 |
|
4 | VIGL |
Vigil Neuroscience, Inc.
Common Stock |
C - Conversion | 1 254 335 | 1 254 335 | |||||
2021-08-18 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 10 000 | 32 943 | 43,59 | 3,00 | 30 000 | 98 829 | |
2021-06-11 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2021-06-04 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy) |
A - Award | 14 000 | 14 000 | |||||
2021-02-12 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −32 873 | 3 433 521 | −0,95 | 4,43 | −145 627 | 15 210 498 |
2020-11-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 2 000 | 22 943 | 9,55 | 3,50 | 7 000 | 80 300 | |
2020-11-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 3 000 | 20 943 | 16,72 | 3,67 | 11 010 | 76 861 | |
2020-11-18 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
J - Other | 10 586 | 15 432 | 218,45 | ||||
2020-11-18 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
J - Other | 2 144 | 17 943 | 13,57 | ||||
2020-11-18 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
J - Other | −52 397 | 0 | −100,00 | ||||
2020-06-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2020-06-05 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy) |
A - Award | 16 000 | 16 000 | |||||
2019-11-26 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
A - Award | 1 518 026 | 4 984 420 | 43,79 | 1,05 | 1 599 999 | 5 253 579 | |
2019-07-03 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −459 | 415 959 | −0,11 | 14,00 | −6 426 | 5 823 426 |
2019-07-03 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −255 | 52 397 | −0,48 | 14,00 | −3 570 | 733 558 |
2019-07-03 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −180 | 162 890 | −0,11 | 14,00 | −2 520 | 2 280 460 |
2019-07-03 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −2 014 | 1 818 638 | −0,11 | 14,00 | −28 196 | 25 460 932 |
2019-06-24 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2019-06-20 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −63 | 416 418 | −0,02 | 14,00 | −882 | 5 829 852 |
2019-06-20 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −35 | 52 655 | −0,07 | 14,00 | −490 | 737 170 |
2019-06-20 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −25 | 163 074 | −0,02 | 14,00 | −350 | 2 283 036 |
2019-06-20 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
S - Sale | X | −277 | 1 820 656 | −0,02 | 14,00 | −3 878 | 25 489 184 |
2019-05-13 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Non-employee Director Stock Option (right to buy) |
A - Award | 11 000 | 11 000 | |||||
2019-03-01 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Employee Stock Option (right to buy) |
A - Award | 36 000 | 36 000 | |||||
2018-12-06 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 4 000 | 15 799 | 33,90 | 3,13 | 12 520 | 49 451 | |
2018-12-06 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 8 000 | 8 000 | 1,36 | 10 880 | 10 880 | ||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | −226 061 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | −24 709 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series D Preferred Stock |
C - Conversion | −272 107 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | −40 420 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | −13 558 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | −149 320 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | −94 874 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | −1 044 764 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock |
C - Conversion | −13 609 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series AA Preferred Stock |
C - Conversion | −174 699 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | −4 846 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | −3 862 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | −42 530 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series 1 Preferred Stock |
C - Conversion | −52 690 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | −994 | 40 420 | −2,40 | 5,00 | −4 970 | 202 100 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
M - Exercise | 41 414 | 41 414 | 0,12 | 4 970 | 4 970 | ||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
M - Exercise | −41 414 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | −104 | 13 558 | −0,76 | 5,00 | −520 | 67 790 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
M - Exercise | 4 309 | 13 662 | 46,07 | 0,12 | 517 | 1 639 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
M - Exercise | −4 309 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
S - Sale | −1 139 | 149 320 | −0,76 | 5,00 | −5 695 | 746 600 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series C-1 Preferred Stock |
M - Exercise | 47 458 | 150 459 | 46,08 | 0,12 | 5 695 | 18 055 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series C-1 Preferred Stock |
M - Exercise | −47 458 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
S - Sale | −42 | 94 874 | −0,04 | 5,00 | −210 | 474 370 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
M - Exercise | 1 731 | 94 916 | 1,86 | 0,12 | 208 | 11 390 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock |
M - Exercise | −1 731 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
S - Sale | −458 | 1 044 764 | −0,04 | 5,00 | −2 290 | 5 223 820 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Series B Preferred Stock |
M - Exercise | 19 061 | 1 045 222 | 1,86 | 0,12 | 2 287 | 125 427 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Warrants to Purchase Series B Preferred Stock |
M - Exercise | −19 061 | 0 | −100,00 | ||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 150 000 | 416 481 | 56,29 | 5,00 | 750 000 | 2 082 405 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 266 481 | 266 481 | |||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 4 846 | 4 846 | |||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 12 487 | 163 099 | 8,29 | 5,00 | 62 435 | 815 495 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 150 612 | 150 612 | |||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
P - Purchase | 137 513 | 1 820 933 | 8,17 | 5,00 | 687 565 | 9 104 665 | |
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 1 683 420 | 1 683 420 | |||||
2018-10-24 |
|
4 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
C - Conversion | 52 690 | 52 690 | |||||
2018-10-17 | 3 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
23 598 | ||||||||
2018-10-17 | 3 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
23 598 | ||||||||
2018-10-17 | 3 | PHAS |
PhaseBio Pharmaceuticals Inc
Common Stock |
23 598 | ||||||||
2018-06-21 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Stock Option (right to buy) |
A - Award | 11 250 | 11 250 | |||||
2018-06-01 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −41 710 | 3 237 711 | −1,27 | 48,00 | −2 002 080 | 155 410 128 | |
2018-06-01 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −758 290 | 3 279 421 | −18,78 | 48,00 | −36 397 920 | 157 412 208 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −26 | 4 037 711 | 0,00 | 50,50 | −1 313 | 203 904 406 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −474 | 4 037 737 | −0,01 | 50,50 | −23 937 | 203 905 718 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −308 | 4 038 211 | −0,01 | 50,69 | −15 611 | 204 677 128 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −5 592 | 4 038 519 | −0,14 | 50,86 | −284 405 | 205 396 249 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −26 | 4 044 111 | 0,00 | 52,13 | −1 355 | 210 819 506 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −474 | 4 044 137 | −0,01 | 52,13 | −24 710 | 210 820 862 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −1 595 | 4 044 611 | −0,04 | 51,06 | −81 439 | 206 513 389 | |
2018-05-23 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
S - Sale | −29 005 | 4 046 206 | −0,71 | 51,16 | −1 483 907 | 207 005 517 | |
2018-05-21 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −61 139 | 3 466 394 | −1,73 | 13,16 | −804 589 | 45 617 745 | |
2018-05-21 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −100 000 | 3 527 533 | −2,76 | 13,03 | −1 303 000 | 45 963 755 | |
2018-03-23 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −5 231 | 3 627 533 | −0,14 | 12,02 | −62 877 | 43 602 947 | |
2018-03-23 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −33 630 | 3 632 764 | −0,92 | 12,07 | −405 914 | 43 847 461 | |
2018-03-23 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −100 000 | 3 666 394 | −2,66 | 12,27 | −1 227 000 | 44 986 654 | |
2017-12-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −5 000 | 3 766 394 | −0,13 | 6,13 | −30 650 | 23 087 995 |
2017-12-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 000 | 3 771 394 | −0,40 | 6,09 | −91 350 | 22 967 789 |
2017-12-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 000 | 3 786 394 | −0,39 | 6,37 | −95 550 | 24 119 330 |
2017-12-04 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
J - Other | 995 | 4 075 211 | 0,02 | ||||
2017-12-04 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
J - Other | −99 513 | 4 074 216 | −2,38 | ||||
2017-11-16 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −5 000 | 3 801 394 | −0,13 | 6,99 | −34 950 | 26 571 744 |
2017-11-16 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 000 | 3 806 394 | −0,39 | 6,99 | −104 850 | 26 606 694 |
2017-11-16 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 000 | 3 821 394 | −0,39 | 7,02 | −105 300 | 26 826 186 |
2017-10-05 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −6 000 | 3 836 394 | −0,16 | 8,34 | −50 040 | 31 995 526 |
2017-10-05 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −14 000 | 3 842 394 | −0,36 | 8,59 | −120 260 | 33 006 164 |
2017-10-05 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 000 | 3 856 394 | −0,39 | 8,64 | −129 600 | 33 319 244 |
2017-09-15 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −10 000 | 3 871 394 | −0,26 | 7,54 | −75 400 | 29 190 311 |
2017-09-15 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −6 000 | 3 881 394 | −0,15 | 7,52 | −45 120 | 29 188 083 |
2017-09-15 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −8 500 | 3 887 394 | −0,22 | 7,49 | −63 665 | 29 116 581 |
2017-08-09 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 000 | 3 895 894 | −0,38 | 7,30 | −109 500 | 28 440 026 |
2017-08-09 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −5 000 | 3 910 894 | −0,13 | 7,98 | −39 900 | 31 208 934 |
2017-08-09 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −4 500 | 3 915 894 | −0,11 | 8,02 | −36 090 | 31 405 470 |
2017-07-05 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Stock Option (right to buy) |
A - Award | 2 632 | 2 632 | |||||
2017-06-23 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Stock Option (right to buy) |
A - Award | 8 618 | 8 618 | |||||
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | −1 009 693 | 0 | −100,00 | ||||
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | −2 584 959 | 0 | −100,00 | ||||
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | −6 568 527 | 0 | −100,00 | ||||
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Series 1 Preferred Stock |
C - Conversion | −1 318 681 | 0 | −100,00 | ||||
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
P - Purchase | 133 333 | 3 861 797 | 3,58 | 15,00 | 1 999 995 | 57 926 955 | |
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
C - Conversion | 99 513 | 99 513 | |||||
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
C - Conversion | 212 419 | 212 419 | |||||
2017-05-24 |
|
4 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
C - Conversion | 3 728 464 | 3 728 464 | |||||
2017-05-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 000 | 3 920 394 | −0,38 | 8,31 | −124 650 | 32 578 474 |
2017-05-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −9 000 | 3 935 394 | −0,23 | 8,44 | −75 960 | 33 214 725 |
2017-05-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −19 000 | 3 944 394 | −0,48 | 8,39 | −159 410 | 33 093 466 |
2017-05-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −9 544 | 3 963 394 | −0,24 | 8,61 | −82 174 | 34 124 822 |
2017-05-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 941 | 3 972 938 | −0,40 | 8,94 | −142 513 | 35 518 066 |
2017-05-17 | 3 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
413 041 | ||||||||
2017-05-17 | 3 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
226 301 | ||||||||
2017-05-17 | 3 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
413 041 | ||||||||
2017-05-17 | 3 | GTHX |
G1 Therapeutics, Inc.
Common Stock |
226 301 | ||||||||
2017-04-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −2 030 | 3 988 879 | −0,05 | 7,37 | −14 961 | 29 398 038 |
2017-04-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −44 455 | 3 990 909 | −1,10 | 7,48 | −332 523 | 29 851 999 |
2017-04-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −22 000 | 4 035 364 | −0,54 | 7,43 | −163 460 | 29 982 755 |
2017-03-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −21 485 | 4 057 364 | −0,53 | 6,77 | −145 453 | 27 468 354 |
2017-03-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −47 000 | 4 078 849 | −1,14 | 6,47 | −304 090 | 26 390 153 |
2017-02-22 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −2 000 | 4 125 849 | −0,05 | 7,49 | −14 980 | 30 902 609 |
2017-02-22 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −25 000 | 4 127 849 | −0,60 | 7,55 | −188 750 | 31 165 260 |
2017-02-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −10 000 | 4 152 849 | −0,24 | 7,54 | −75 400 | 31 312 481 |
2017-02-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −14 000 | 4 162 849 | −0,34 | 7,58 | −106 120 | 31 554 395 |
2017-02-17 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −17 485 | 4 176 849 | −0,42 | 7,64 | −133 585 | 31 911 126 |
2017-01-20 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −8 000 | 4 194 334 | −0,19 | 7,77 | −62 160 | 32 589 975 |
2017-01-20 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −15 485 | 4 202 334 | −0,37 | 8,23 | −127 442 | 34 585 209 |
2017-01-20 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −25 000 | 4 217 819 | −0,59 | 8,64 | −216 000 | 36 441 956 |
2017-01-20 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | X | −20 000 | 4 242 819 | −0,47 | 8,92 | −178 400 | 37 845 945 |
2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −7 592 | 2 060 514 | −0,37 | 8,22 | −62 406 | 16 937 425 | |
2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −12 258 | 2 068 106 | −0,59 | 8,64 | −105 909 | 17 868 436 | |
2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −9 806 | 2 080 364 | −0,47 | 8,92 | −87 470 | 18 556 847 | |
2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −6 478 | 1 757 719 | −0,37 | 8,22 | −53 249 | 14 448 450 | |
2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −10 457 | 1 764 197 | −0,59 | 8,64 | −90 348 | 15 242 662 | |
2017-01-19 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −8 366 | 1 774 654 | −0,47 | 8,92 | −74 625 | 15 829 914 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | −21 705 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series C Preferred Stock |
C - Conversion | −337 897 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series B Preferred Stock |
C - Conversion | −432 941 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A-1 Preferred Stock |
C - Conversion | −689 388 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A Preferred Stock |
C - Conversion | −2 035 908 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 414 286 | 2 090 170 | 24,72 | 7,00 | 2 900 002 | 14 631 190 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −69 | 1 675 884 | 0,00 | 7,00 | −483 | 11 731 188 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
X - Other | 21 705 | 1 675 953 | 1,31 | 0,02 | 478 | 36 871 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
C - Conversion | 1 598 223 | 1 654 248 | 2 852,70 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | −1 805 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | −19 900 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series C Preferred Stock |
C - Conversion | −337 898 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series B Preferred Stock |
C - Conversion | −432 940 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A-1 Preferred Stock |
C - Conversion | −689 388 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A Preferred Stock |
C - Conversion | −2 035 907 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 107 142 | 1 783 020 | 6,39 | 7,00 | 749 994 | 12 481 140 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −69 | 1 675 878 | 0,00 | 7,00 | −483 | 11 731 146 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
X - Other | 21 705 | 1 675 947 | 1,31 | 0,02 | 478 | 36 871 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
C - Conversion | 1 598 219 | 1 654 242 | 2 852,79 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | −21 705 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | −1 805 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Warrant to Purchase Common Stock (right to buy) |
X - Other | −19 900 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series C Preferred Stock |
C - Conversion | −675 795 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series B Preferred Stock |
C - Conversion | −865 881 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A-1 Preferred Stock |
C - Conversion | −1 654 531 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Series A Preferred Stock |
C - Conversion | −4 071 815 | 0 | −100,00 | ||||
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
P - Purchase | 785 714 | 4 262 819 | 22,60 | 7,00 | 5 499 998 | 29 839 733 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
S - Sale | −138 | 3 477 105 | 0,00 | 7,00 | −966 | 24 339 735 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
X - Other | 43 410 | 3 477 243 | 1,26 | 0,02 | 955 | 76 499 | |
2016-06-07 |
|
4 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
C - Conversion | 3 321 785 | 3 433 833 | 2 964,61 | ||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
224 096 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
224 096 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 050 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 | ||||||||
2016-06-01 | 3 | CLSD |
Clearside Biomedical, Inc.
Common Stock |
112 046 |